GRACE :: Breast Cancer

Chemotherapy

Dr West

Dr. Hy Muss on Breast Cancer in Older Women: Advanced/Metastatic Cancer and Importance of Functional Status

Share

Dr. Muss closes his presentation with a discussion of the importance of assessing functional status of older patients with breast cancer, as well as other cancers, in making recommendations for the optimal treatment approach.  Here he describes the potential value of more aggressive treatments, along with the need to be judicious in our recommendations in order to reduce the risk of patients developing prohibitive side effects from the therapy.

Below you’ll find the video and audio versions of the podcast along with the transcript and figures for this program.

Muss BC in Older Women Pt 4 Advanced BC and Functional Assessment Audio Podcast

Muss BC in Older Women Pt 4 Advanced BC and Functional Assessment Transcript

Muss BC in Older Women Pt 4 Advanced BC and Functional Assessment Figs

Continue reading


Dr West

Breast Cancer in Older Women: Surgery and Adjuvant Therapy, by Dr. Hy Muss

Share

Dr. Hy Muss, breast cancer expert with a special expertise in treatment of older patients with cancer, continues his presentation on breast cancer in older women with a discussion of the evolution of surgery recommendations in breast cancer, along with a wonderful discussion of how he approaches the benefit vs. risk discussion for post-operative (adjuvant) therapy.  I found myself thinking that his explanation was so helpful that I’d want to incorporate elements of his presentation into my own discussions of the complex issues around adjuvant therapy.

Here are the video and audio versions of the program, along with the associated transcript and figures.

Muss BC in Older Women Pt 3 Surgery and Adjuvant Rx Audio Podcast

Muss BC in Older Women Pt 3 Surgery and Adjuvant Rx Transcript

Muss BC in Older Women Pt 3 Surgery and Adjuvant Rx Figures

Continue reading


Perjeta (Pertuzumab) Approved by FDA for HER2-Positive Advanced Breast Cancer

Share

On June 8, The U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab) to treat patients with metastatic, HER2-positive breast cancer who have not received previous treatment with either chemotherapy or HER2-targeted therapy. Approximately 20-30% of breast cancer is HER2-positive.

Herceptin is a monoclonal antibody that works by blocking HER2. While Perjeta also targets HER2, it binds to a different area of the HER2 protein and prevents the HER2 protein from combining with other HER receptors (HER1, HER3, and HER4). This prevents tumor growth and survival. Perjeta’s mechanism of action is therefore believed to be complimentary to that of Herceptin. In fact, Perjeta by itself has very little activity; its real use is in combination with Herceptin.

Continue reading


Ask Us, Q&A
Breast Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243